Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading Update

14 Oct 2020 07:00

RNS Number : 9815B
Synthomer PLC
14 October 2020
 

October 14th 2020

 

Synthomer plc

 

Q3 Trading Update

 

FY2020 EBITDA guidance raised 10%, interim dividend reinstated and pro forma leverage expected to reduce to circa 2.0x EBITDA by end of 2020

 

Synthomer plc ("Synthomer" or "the Group") today brings forward its update on trading for the third quarter ("Q3") ended September 30th 2020.

 

Strong trading momentum across all three business divisions

 

Performance Elastomers volumes and margins are ahead of prior year reflecting strong demand in Nitrile Latex following the COVID-19 pandemic and improved conditions in SBR latex through Q3.

 

Functional Solutions continued to benefit from the integration of OMNOVA and likewise is trading ahead of prior year albeit some market sectors are demonstrating stronger resilience than others. End market and geographic diversification remains a key strength of our Functional Solutions business.

 

Industrial Specialities continued to improve in Q3 following a weaker Q2 impacted by COVID-19. Current run rate volumes and margins are on or above prior year.

 

FY EBITDA guidance raised 10%

 

At the time of its Interim Results in August, the Group said that it expected FY 2020 EBITDA to be broadly-in-line with market consensus of £211 million (source Teneo). Synthomer now expects FY 2020 EBITDA to be circa £232 million, 10% higher than where it was envisaged to be in August.

 

Proforma leverage expected to reduce to circa 2.0x EBITDA

 

The Group remains highly cash generative and now expects proforma leverage to reduce to circa 2.0x net debt to EBITDA by December 2020.

 

Interim dividend reinstated

 

As a result of the Group's strong trading performance and cash generation, the Board has decided to reinstate the interim dividend which was suspended in April. The Board has declared an interim dividend of 3.0 pence per share payable on November 10th 2020 to shareholders on the register at close of business on October 23rd 2020. The Board has also fully reinstated its existing dividend policy and intends to pay a final dividend in line with its capital policy.

 

Further strategic progress

 

The integration of OMNOVA is proceeding ahead of schedule. As previously stated, the Group now expects synergies to achieve a $20 million run rate by the end of year (increased from $15 million) and a $40 million run rate by the end of 2022 (increased from $30 million).

 

In August, the Group confirmed that it was in a consultation process with employees at its SBR site in Oulu (Finland) concerning future options for the site. The consultation process at Oulu is complete and the decision has been made to close this site by the end of Q1 2021. Consultations are continuing at Marl (Germany) with an outcome expected in Q4 this year. Synthomer remains committed to the SBR markets in Europe and is confident of being able to service customers from its Central European asset base. 

 

Our additional Nitrile Latex capacity in Malaysia is on schedule for beneficial operation in Q4 2021 to further support the strong demand we have seen following the COVID-19 pandemic.

 

 

Calum MacLean, Chief Executive of Synthomer said:

 

"This is a very encouraging performance with all business divisions performing ahead of prior year. Alongside this strong momentum, we have made significant strategic progress, with a decision to close our site in Oulu and the integration of OMNOVA continuing ahead of our initial expectations. This underpins our confidence for the remainder of this year and beyond leading to an upgrade to our guidance for the full year and reinstating our interim dividend."

 

 

Further information:

 

The Company will hold a conference call for investors and analysts at 0900 BST today:

Dial in number: 08003589473 PIN: 69896742#

 

 

Calum MacLean, Chief Executive Officer

 

Steve Bennett, Chief Financial Officer

Tel: + 44 1279 436211

Tim Hughes, President, Corporate Development

 

 

 

Charles Armitstead/ Matt Denham, Teneo

Tel: + 44 7703 330 269/ + 44 7825 735596

 

 

Investor Seminar

Synthomer will be hosting an Investor Seminar on Wednesday 18th November to focus on the Group's strategy post its acquisition of OMNOVA, with a particular focus on its Functional Solutions business.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOVBRRUURAAA
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.